A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

Phase 1 Recruiting 108 enrolled Zhuhai Fapon Biopharma Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The goal of the phase 1 study is to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics activity of FP008 in subjects with advanced solid tumors.

Timeline

Start: 2025-06-12
Primary completion: 2028-05
Completion: 2028-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	FP008	Unknown	—	Intravenous

A Phase 1 Study to Investigate FP008 in Subjects With Advanced Solid Tumors

Summary

Timeline

Drugs

Indications